Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CEO Sells $223,783.56 in Stock

SI-BONE, Inc. (NASDAQ:SIBNGet Rating) CEO Laura Francis sold 9,009 shares of the firm’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $24.84, for a total transaction of $223,783.56. Following the completion of the transaction, the chief executive officer now directly owns 445,836 shares of the company’s stock, valued at approximately $11,074,566.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Laura Francis also recently made the following trade(s):

  • On Tuesday, February 28th, Laura Francis sold 35,000 shares of SI-BONE stock. The stock was sold at an average price of $20.23, for a total transaction of $708,050.00.

SI-BONE Trading Up 0.4 %

SIBN stock opened at $26.22 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.65 and a current ratio of 7.72. The firm’s fifty day moving average is $21.33 and its 200 day moving average is $17.30. SI-BONE, Inc. has a one year low of $11.14 and a one year high of $27.24.

SI-BONE (NASDAQ:SIBNGet Rating) last announced its earnings results on Monday, February 27th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.10. SI-BONE had a negative net margin of 47.11% and a negative return on equity of 54.17%. The business had revenue of $31.95 million for the quarter, compared to analyst estimates of $31.80 million. On average, sell-side analysts forecast that SI-BONE, Inc. will post -1.44 EPS for the current fiscal year.

Institutional Trading of SI-BONE

Institutional investors have recently modified their holdings of the stock. FMR LLC grew its position in shares of SI-BONE by 28.7% in the first quarter. FMR LLC now owns 2,160 shares of the company’s stock valued at $42,000 after purchasing an additional 482 shares during the period. Larson Financial Group LLC acquired a new stake in shares of SI-BONE in the first quarter valued at about $49,000. Ensign Peak Advisors Inc acquired a new stake in shares of SI-BONE in the third quarter valued at about $48,000. Tower Research Capital LLC TRC grew its position in shares of SI-BONE by 151.1% in the third quarter. Tower Research Capital LLC TRC now owns 3,398 shares of the company’s stock valued at $60,000 after purchasing an additional 2,045 shares during the period. Finally, UBS Group AG grew its position in shares of SI-BONE by 29.5% in the third quarter. UBS Group AG now owns 4,850 shares of the company’s stock valued at $84,000 after purchasing an additional 1,105 shares during the period. Institutional investors and hedge funds own 98.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SIBN. Morgan Stanley increased their price objective on shares of SI-BONE from $18.00 to $22.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 28th. Cantor Fitzgerald increased their price objective on shares of SI-BONE from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 28th. Needham & Company LLC increased their price objective on shares of SI-BONE from $24.00 to $27.00 in a research note on Tuesday, May 2nd. Truist Financial increased their price objective on shares of SI-BONE from $26.00 to $28.00 in a research note on Tuesday, May 2nd. Finally, Canaccord Genuity Group increased their price objective on shares of SI-BONE from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, February 28th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.29.

About SI-BONE

(Get Rating)

SI-BONE, Inc engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain.

Featured Articles

Insider Buying and Selling by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.